Herpes zoster and the immunocompromised (Q39758708)

14 September 2017

1 reference

title

Herpes zoster and the immunocompromised (English)

1 reference

14 September 2017

1 reference

Mandal BK

1

1 reference

14 September 2017

publication date

1 January 1987

1 reference

14 September 2017

1 reference

14 September 2017

volume

14

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

1-5

1 reference

Selective decline in cellular immune response to varicella-zoster in the elderly

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Prolonged Herpes-Zoster Infection Associated with Immunosuppressive Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Cellular and Humoral Immunity in the Pathogenesis of Recurrent Herpes Viral Infections in Patients with Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Cell-Mediated Immunity to Varicella-Zoster Virus after Allogeneic Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Cellular Immunity and Herpesvirus Infections in Cardiac-Transplant Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Serum Antibody Levels as Risk Factors in the Dissemination of Herpes Zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Herpes zoster at the NIH: A 20 year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Varicella-Zoster infection in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

The incidence of herpes zoster in patients with Hodgkin's disease. An analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Herpes zoster after irradiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Herpes zoster in patients with small-cell carcinoma of the lung receiving combined modality treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Herpes zoster and small cell bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Infection with varicella-zoster virus after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

A Longitudinal Study of Varicella-Zoster Virus Infections in Renal Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Clinically evident, non-terminal infections with herpesviruses and the wart virus in immunosuppressed renal allograft recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Varicella-zoster infections in pediatric renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Herpes zoster in patients with treated Wegener's granulomatosis. A possible role for cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Herpes zoster in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Shingles in seven homosexuals

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Population-based study of herpes zoster and its sequelae

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Human Leukocyte Interferon for the Treatment of Herpes Zoster in Patients with Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Toxicity of interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Acyclovir administered perorally in immunocompromised children with varicella-zoster infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

High-dose oral acyclovir for children at risk of disseminated herpesvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Amino (hydroxyethoxymethyl) purine: a new well-absorbed prodrug of acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Prophylactic oral acyclovir after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2887%2990652-9

7 January 2021

10.1016/S0163-4453(87)90652-9

Identifiers

DOI

1 reference

14 September 2017

1 reference